Triple Therapy of Intravitreal Triamcinolone, Photodynamic Therapy, and Pegaptanib Sodium for Choroidal Neovascularization

详细信息	查看全文 | 推荐本文 |

• 作者：Peter E. Liggett ; Juner Colina ; Nauman A. Chaudhry ; David Tom ; Gregory Haffner
• 刊名：American Journal of Ophthalmology
• 出版年：2006
• 期刊代码：7_00029394
• 类别：med
• 出版时间：December 2006
• 卷：142
• 期：6
• 页码：1072-1074
• 文件大小：1130 K

摘要

Purpose

To report the six-month results of subfoveal choroidal neovascularization that had been treated with combined therapy of high-dose intravitreal triamcinolone acetonide (HDIVTA), photodynamic therapy (PDT), and pegaptanib sodium injection.

Design

Retrospective, interventional case series study.

Methods

Medical files of 16 patients with this treatment were reviewed (22 eyes); 13 eyes had had previous treatment with HDIVTA and PDT; nine eyes were newly diagnosed choroidal neovascularization. Patients were treated with an injection of HDIVTA (10 mg), followed by PDT and pegabtanib sodium injection at two-week intervals. The main outcome variables were visual acuity (VA) and macular thickness by optical coherence tomography (OCT).

Results

The mean VA improved 2.2 lines (P = .013 in the new treatment group); the previous treatment group (HDIVTA + PDT) improved only 0.7 lines (P = 0.55, Wilcoxon ranked test). The mean of macular thickness before and after treatment was statistically significant in both groups.

Conclusion

This combination therapy showed improvement and/or stabilization in VA, particularly when used as first-line therapy.